Skip to content

Academic clinical study to evaluate performance of Refirm Dental Implants

Survival rate of a Titanium alloy Dental Implant with novel macro form – an Academic Clinical Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/08/035411
Enrollment
300
Registered
2021-08-04
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K069- Disorder of gingiva and edentulousalveolar ridge, unspecified

Interventions

Intervention1: Dental Implants: Placement of Dental implant and restoration of single tooth. Study period is 9 months form date of implant placement. Overall study period is less than or equal to one

Sponsors

Intessence Solutions Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The patient is between 20 to 50 years of age. Possesses ability to understand and provide informed consent before starting the study. Has the ability and willingness to comply with all study requirements. Follows adequate oral hygiene to allow for implant therapy consistent with standards of care

Exclusion criteria

Exclusion criteria: Female patients who are pregnant or planning a pregnancy in the next 1 year , Nursing Mothers. Patient reports tobacco use within the last five years, current smoking habit with moderate or heavy smoking (more than 10 cigarettes per day) or tobacco chewing. History of alcoholism or drug abuse within the past 5 years

Design outcomes

Primary

MeasureTime frame
%age of implants survival at 3 months post loading Placement torque values Timepoint: %age of implants survival at 3 months post loading Placement torque values

Secondary

MeasureTime frame
Ease of placement of implants, Drill life & performance, Ease of use of healing abutments Timepoint: At the time of usage of the various accessories

Countries

India

Contacts

Public ContactDr Raghavendra S

Intessence Solutions Pvt. Ltd.

raghavendra.s@intessence.in08041705021

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026